首页 | 本学科首页   官方微博 | 高级检索  
检索        

药物洗脱支架内再狭窄再次置人支架的远期疗效和安全性
引用本文:随永刚,滕思勇,裴汉军,吴永健,杨跃进,乔树宾,陈珏,姚民,刘海波,尤士杰,袁晋青,戴军,高润霖.药物洗脱支架内再狭窄再次置人支架的远期疗效和安全性[J].疑难病杂志,2014(6):555-557.
作者姓名:随永刚  滕思勇  裴汉军  吴永健  杨跃进  乔树宾  陈珏  姚民  刘海波  尤士杰  袁晋青  戴军  高润霖
作者单位:北京协和医学院/中国医学科学院心血管病研究所/阜外心血管病医院冠心病诊疗中心,100037
摘    要:目的探讨对药物洗脱支架(DES)置入后发生再狭窄(ISR)患者再次实施DES置入术的远期疗效和安全性。方法选择植入DES的冠心病患者,经冠状动脉造影检查证实发生再狭窄(ISR≥50%),并且再次置入DES治疗ISR介入手术成功的患者。985例DES-ISR患者根据狭窄类型分为局限性狭窄组130例(13.2%),弥漫性狭窄组699例(71.0%),闭塞性狭窄组156例(15.8%)。随访观察3组患者的远期(6个月、12个月)疗效及安全性。结果经过6个月的随访,局限性狭窄组患者主要不良心血管事件(MACE)的发生率为3.85%(5/130);弥漫性狭窄组患者MACE的发生率为2.72%(19/699);闭塞狭窄组患者MACE的发生率为3.21%(5/156),3组6个月的随访结果差异无统计学意义(P>0.05)。经过12个月的随访,局限性狭窄组患者MACE的发生率为13.08%(17/130);弥漫性狭窄组患者MACE的发生率为9.16%(64/699);闭塞狭窄组患者MACE的发生率为9.62%(15/156),3组12个月的随访结果差异亦无统计学意义(P>0.05)。结论目前对于DES-ISR患者来说,不论ISR的类型,再次置入DES都是一种有效的方法。

关 键 词:药物洗脱支架  支架内再狭窄  支架再次置入  远期疗效  安全性

Long-term safety and efficacy of re-implementation of drug eluting stent in implantation restenosis patients
SUI Yonggang,TENG Siyong,PEI Hanjun,WU Yonjian,YANG Yuefin,QIAO Shubin,CHEN Jue,YAO Min,LIU Haibo,YOU Shi- fie,YUAN Jinqing,DAI Jun,GAO Runlin.Long-term safety and efficacy of re-implementation of drug eluting stent in implantation restenosis patients[J].Journal of Difficult and Complicated Cases,2014(6):555-557.
Authors:SUI Yonggang  TENG Siyong  PEI Hanjun  WU Yonjian  YANG Yuefin  QIAO Shubin  CHEN Jue  YAO Min  LIU Haibo  YOU Shi- fie  YUAN Jinqing  DAI Jun  GAO Runlin
Institution:. (Department of Cardiology, Cardiovascular Institute and Fuwai Hospital, CAMS and PUMC, Beifing 100037, China )
Abstract:Objective To observe the long-term safety and efficacy of drug eluting stent (DES) implantation restenosis (ISR) patients're-implementation of DES implantation. Methods Selected DES implantation in patients with coronary heart disease, coronary angiography examination confirmed the occurrence of restenosis ( ISR ≥ 50% ), and once again in the DES intervention ISR operation successful patients. 985 cases of DES ISR patients according to narrow type were divided into localized stenosis group with 130 cases (13.2%), diffuse stenosis group with 699 cases (71.0%), occlusive stenosis group with 156 cases ( 15.8% ). Long ternl follow-up observation of efficacy and safety in the 3 groups (6 months, 12 months). Results After 6 months of follow-up, localized stenosis group with major adverse cardiovascular events (MACE) occurred in 3.85% (5/130) ; in diffuse stenosis group, the incidence of MACE was 2.72% (19/699) ; in occlusion stenosis group, the incidence of MACE was 3.21% (5/156), no statistically significant of 6 month follow-up were found among 3 groups ( P 〉 0.05). After 12 months of follow-up, localized stenosis groupsqneidenee of MACE was 13.08% (17/130) ; in diffuse steno- sis group, the incidence of MACE was 9.16% (64/699) ; in occlusion stenosis group, the incidence of MACE was 9.62% (15/156) , the follow-up results of 3 groups of 12 months had no statistical difference significance ( P 〉 0.05 ). Conclusion It demonstrated that the re-implementation DES implantation was an effective alternative for treatment of DES ISR.
Keywords:Drug eluting stents  In-stent restenosis  Repeat drug eluting stents implantation  Long term efficacy  Safety
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号